Investing in biotechnology companies before they become profitable is a risky business. It becomes less so, however, when the firm boasts a proprietary technology, growing sales of products on the market, a promising pipeline and collaboration agreements with big pharmaceutical companies., a biotech with a market value of $20bn, fulfils these conditions, and should become profitable
The leading player in a lucrative niche
Oct 27, 2023
2 minutes
You’re reading a preview, subscribe to read more.
Start your free 30 days